# Safety and Efficacy Study of Femara(Letrozole) as an Extended Adjuvant Treatment in Breast Cancer Patients

> **NCT01249456** · — · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 392 (actual)

## Conditions studied

- Breast Cancer
- Letrozole

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT01249456
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2006-05
- **Primary completion:** 2015-04
- **Final completion:** 2015-04
- **Target enrollment:** 392 (ACTUAL)
- **Last updated:** 2015-06-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01249456

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01249456, "Safety and Efficacy Study of Femara(Letrozole) as an Extended Adjuvant Treatment in Breast Cancer Patients". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01249456. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*